Free Trial
NASDAQ:PSTV

Plus Therapeutics Q2 2025 Earnings Results & Report

Plus Therapeutics logo
$0.95 +0.18 (+23.32%)
As of 11/13/2026

Plus Therapeutics beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$0.25 versus the -$2.25 consensus estimate, while revenue of $1.39 million topped the $1.08 million estimate by $310.00 thousand.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens
Conference Call
4:00 PM ET

Plus Therapeutics EPS Results

Actual EPS
-$0.25
Consensus EPS
-$2.25
Beat/Miss
Beat by +$2.00
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Plus Therapeutics Revenue Results

Actual Revenue
$1.39 million
Expected Revenue
$1.08 million
Beat/Miss
Beat by +$310.00 thousand
YoY Revenue Growth
N/A

Plus Therapeutics Q2 2025 Earnings FAQ

Plus Therapeutics (NASDAQ:PSTV) reported earnings of -$0.25 per share for Q2 2025, beating the consensus estimate of -$2.25. The report was announced on Thursday, August 14, 2025.

Plus Therapeutics reported revenue of $1.39 million for Q2 2025, against a consensus estimate of $1.08 million.

Plus Therapeutics Earnings Headlines

Plus Therapeutics (NASDAQ:PSTV) Stock Falls 4.1% - What's Next?
Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Plus Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Plus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Plus Therapeutics and other key companies, straight to your email.

About Plus Therapeutics

Plus Therapeutics (NASDAQ:PSTV) is a clinical-stage biotechnology company developing targeted treatments and diagnostic tools for cancers affecting the central nervous system. Its work includes radiopharmaceutical therapies designed to deliver radiation to tumors while limiting exposure to surrounding healthy tissue.

The company’s lead therapeutic program is Rhenium-186 NanoLiposome (RNL), an investigational treatment being studied for cancers including recurrent glioblastoma and leptomeningeal metastases. Plus Therapeutics also develops CNSide, a diagnostic platform intended to help detect and monitor cancer cells in cerebrospinal fluid.

Previously known as Cytori Therapeutics, the company adopted the Plus Therapeutics name in 2019. It is based in the United States and focuses its development programs on cancers of the brain and central nervous system.

View Plus Therapeutics Profile